Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)

Decroisette, C.; Monnet, I.; Bérard, H.; Quéré, Gilles; Caer, H. Le; Bota, Suzanna; Audigier-Valette, Clarisse; Gérinière, L.; Vernejoux, J.-M.; Chouaïd, C.

doi:10.1097/jto.0b013e318206a1e3

Cited by 112 publications

(111 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are several articles that have examined the health care utilization and cost associated with the management of general bony metastasis and its associated "skeletal events," with some providing a subanalysis of spinal column metastasis. 8,13,14,17 These studies contain a heterogeneous cohort of patients, but offer a valuable sense of the expense associated with the management of bony metastasis. The average cost of treating a skeletal event secondary to metastasis is reported to range from $10,000 to $12,000.…”

Section: Discussionmentioning

confidence: 99%

“…There is a paucity of studies that directly evaluate the cost of surgery for spinal tumors. 9,12,34,41,44 Many of the past studies have focused on the health care costs associated with managing (medically and/or surgically) heterogeneous cohorts of patients with bony metastasis 8,13,14,17 or evaluated the cost effectiveness of adjuvant radiotherapy for spinal metastasis. 15 In addition, among those studies there is a lack of details regarding the type of procedure performed or a dedicated analysis of the factors that affect cost.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Costs and readmission rates for the resection of primary and metastatic spinal tumors: a comparative analysis of 181 patients

Lau¹,

Chan²,

Theologis

et al. 2016

SPI

View full text Add to dashboard Cite

OBJECTIVE Because the surgical strategies for primary and metastatic spinal tumors are different, the respective associated costs and morbidities associated with those treatments likely vary. This study compares the direct costs and 90-day readmission rates between the resection of extradural metastatic and primary spinal tumors. The factors associated with cost and readmission are identified. METHODS Adults (age 18 years or older) who underwent the resection of spinal tumors between 2008 and 2013 were included in the study. Patients with intradural tumors were excluded. The direct costs of index hospitalization and 90-day readmission hospitalization were evaluated. The direct costs were compared between patients who were treated surgically for primary and metastatic spinal tumors. The independent factors associated with costs and readmissions were identified using multivariate analysis. RESULTS A total of 181 patients with spinal tumors were included (63 primary and 118 metastatic tumors). Overall, the mean index hospital admission cost for the surgical management of spinal tumors was $52,083. There was no significant difference in the cost of hospitalization between primary ($55,801) and metastatic ($50,098) tumors (p = 0.426). The independent factors associated with higher cost were male sex (p = 0.032), preoperative inability to ambulate (p = 0.002), having more than 3 comorbidities (p = 0.037), undergoing corpectomy (p = 0.021), instrumentation greater than 7 levels (p < 0.001), combined anterior-posterior approach (p < 0.001), presence of a perioperative complication (p < 0.001), and longer hospital stay (p < 0.001). The perioperative complication rate was 21.0%. Of this cohort, 11.6% of patients were readmitted within 90 days, and the mean hospitalization cost of that readmission was $20,078. Readmission rates after surgical treatment for primary and metastatic tumors were similar (11.1% vs 11.9%, respectively) (p = 0.880). Prior hospital stay greater than 15 days (OR 6.62, p = 0.016) and diagnosis of lung metastasis (OR 52.99, p = 0.007) were independent predictors of readmission. CONCLUSIONS Primary and metastatic spinal tumors are comparable with regard to the direct costs of the index surgical hospitalization and readmission rate within 90 days. The factors independently associated with costs are related to preoperative health status, type and complexity of surgery, and postoperative course.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Costs and readmission rates for the resection of primary and metastatic spinal tumors: a comparative analysis of 181 patients

Lau¹,

Chan²,

Theologis

et al. 2016

SPI

View full text Add to dashboard Cite

show abstract

“…Several retrospective studies have highlighted the increase in treatment costs as patients with lung cancer progress to metastatic bone disease and experience associated SREs (14)(15)(16)(17)(18). A prospective study in France also highlighted the high cost of care of patients with SREs, with 50% of the cost for the treatment of patients with lung cancer who have bone metastases being linked to the occurrence of SREs (19). Although these data provide some insight into the impact that lung cancer-associated SREs have on healthcare systems, there is generally a lack of prospective data from a broader European population.…”

Section: Health Resource Utilisation Associated With Skeletal-relatedmentioning

confidence: 99%

Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational study

Lorusso¹,

Durán

Garzón-Rodríguez

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Bone complications or skeletal-related events (SREs), typically defined as radiation to bone, pathological fractures, surgery to bone and spinal cord compression, occur frequently in patients with bone metastases. As the survival of patients with advanced lung cancer improves, preventing SREs is becoming increasingly clinically relevant. The aim of this analysis was to assess the impact of SREs on health resource utilisation (HRU) in European lung cancer patients with bone metastasis. This multinational, observational study included patients who had at least one SRE in the 97 days prior to enrolment, a life expectancy of ≥6 months and an Eastern Cooperative Oncology Group performance status of 0-2. Data on HRU were retrospectively collected for up to 97 days prior to enrolment with a planned prospective follow-up for up to 18-21 months. The HRU measures included the number and length of inpatient hospitalisations and the number of outpatient visits and procedures. The investigators determined whether each HRU was attributable to a SRE. In total, 135 patients with lung cancer, enrolled at centres in Germany, Italy, Spain and the United Kingdom, contributed 214 SREs to this analysis. The median length [quartile (Q)1, Q3] of follow-up ranged from 1.5 (0.7, 3.3) to 5.6 (2.0, 8.2) months across the countries. Overall, 41% of the SREs required an inpatient stay, with a median (Q1, Q3) duration of 19.0 (6.0, 28.0) days. Spinal cord compression and surgery to bone were the SRE types most frequently requiring inpatient stays. Radiation to bone was associated with the largest number of outpatient visits and procedures. All the SREs resulting from bone metastases in patients with lung cancer contribute considerably to HRU and efforts to minimise the incidence of bone complications in these patients through appropriate treatments may help reduce this burden.

show abstract

“…[16,19] nepoznatog porekla, 9,4% [2,4,5,6,7,11,16,17,21]. Kod solitarne koštane metastaze nastale od karcinoma bubrega i štitne žlezde, operativna terapija je bila agresivna zbog očekivanog dugog preživljavanja [3,8,9,11,18,20].…”

Section: Analitičke Statističke Metodeunclassified

“…Ovo je zbog toga što ovoj grupi pripadaju tumori veoma agresivnog ponašanja i veoma kratkog preživljavanja bolesnika, prema tome snažan negativan prognostički faktor za preživljavanje je primarni tumor iz ove grupe, a to je najčešće karcinom pluća [10,11,12,19]. Danas postoje različiti skoring sistemi, koji pomažu u odluci hirurga o operativnom lečenju, zasnovani na dužini preživljavanja, kao što su Bauerov skor, Katagiri skor, Tomita skoring sistem, Capanna skoring, Tokuhashi skoring sistem, Soitous skor, Van der Linden skor [12,13,14,15,16,17].…”

Section: Wwwtmgorgrsunclassified

Survival analysis of patients with operable skeletal metastases in apendicular skeleton

Maljković¹,

Vučinić²,

Djordjević³

2014

Tim Med Glas

View full text Add to dashboard Cite

(1) OPŠTA BOLNICA SREMSKA MITROVICA, (2) IOH "BANJICA" BEOGRAD Sažetak:Skeletne metastaze su najčešći maligni tumori kosti koji su 25 puta češći od primarnih malignih tumora kosti. Kod žena, tumori dojke i pluća su odgovorni za 80% skeletnih metastaza, dok su kod muškaraca, tumori prostate i pluća odgovorni za 80% skeletnih metastaza. U Srbiji se godišnje otkrije preko 32000 novih bolesnika sa malignim tumorima. Oko polovine ovih bolesnika će u nekom periodu svog života razviti skeletne metastaze. Cilj istraživanja: U studiji smo analizirali vrednost vrste primarnog tumora kao prognostičkog faktora preživljavanja kod 32 pacijenta sa skeletnim metastazama dugih cevastih kostiju operisanih u IOH "Banjica", Beograd i u Opštoj bolnici Sremska Mitrovica. Materijal i metode: U studiju su uključena 32 pacijenta koja su operisana zbog skeletne metastaze. Podaci su bili analizirani statističkim deskriptivinim metodama i analitičkim statističkim metodama (T-test, Kaplan-Meierova kriva preživljavanja i Cox regresioni model proporcionalnih rizika). Grupa je podeljena u dve podgrupe: primarni tumori sa umerenim rastom (Ca. bubrega, dojke, prostate i štitne žlezde) i primarni tumori sa rapidnom brzinom rasta tumora (Ca. pluća, uterusa, melanom i Ca. nepoznatog porekla). Da li izmeĎu dve podgrupe prognostičkih faktora postoji statistički značajna razlika u preživljavanju, biće odreĎeno T-testom. Rezultati: Analitičkim, statističkim metodama je dokazan jak uticaj primarnog tumora na preživljavanje ovih bolesnika. Ovaj prognostički faktor je jedan od najvažnijih za odreĎivanje očekivane dužine života koja je odlučujuća za odluku o operativnom lečenju i vrsti operativne terapije, i deo je svih skoring sistema za predviĎanje očekivane dužine života pacijenata sa skeletnim metastazama. Zaključak: Tip primarnog tumora je jak, nezavisan prognostički faktor preživljavanja bolesnika sa operativno lečenim skeletnim metastazama. Solitarna skeletna metastaza karcinoma bubrega je i u ovom radu izdvojena kao poseban ortopedski entitet zbog mogućnosti dugogodišnjeg preživljavanja ovih bolesnika. Kod primarnih tumora umerenog rasta treba birati dugotrajne i agresivnije hirurške procedure rekonstrukcije postekscizionog defekta kosti zbog dužeg preživljavanja. Ključne reči: prognostički faktor preživljavanja, primarni tumor, skeletne metastaze, očekivana dužina života. Summary:Skeletal metastases are the most common skeletal cancers that occur 25 times more than primary bone tumours. Breast and lung cancers are the primary sites that cause 80% of total skeletal metastases at female patients, while prostate and lung cancers are the primary sites that cause 80% of total skeletal metastases at male patients. 32.000 new patients with malignant tumours are registered in Serbia every year. The estimation is that in 50% of these patients skeletal metastases will occur during their life span. In this paper, the results of surgical treatment performed at 32 patients with limb metastases were evaluated. Scope: This study evaluates the primary tumours as ...

show abstract

Epidemiology and Treatment Costs of Bone Metastases from Lung Cancer: A French Prospective, Observational, Multicenter Study (GFPC 0601)

Abstract: This analysis confirms the poor prognosis of BMD from lung cancer and underlines the burden of SRE in overall treatment costs.

Cited by 112 publications

References 20 publications

Costs and readmission rates for the resection of primary and metastatic spinal tumors: a comparative analysis of 181 patients

Costs and readmission rates for the resection of primary and metastatic spinal tumors: a comparative analysis of 181 patients

Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Α subgroup analysis from a prospective multinational study

Survival analysis of patients with operable skeletal metastases in apendicular skeleton

Contact Info

Product

Resources

About